ZNF529 inhibitors are a class of chemical compounds specifically designed to target and modulate the activity of the ZNF529 protein, a member of the zinc finger protein family. Zinc finger proteins, including ZNF529, are characterized by their zinc finger motifs, which are structural domains that facilitate binding to DNA, RNA, or other proteins. ZNF529, like many other zinc finger proteins, is believed to function as a transcription factor, playing a crucial role in the regulation of gene expression. By binding to specific DNA sequences, ZNF529 likely influences the transcription of target genes involved in various cellular processes, including development, differentiation, and cellular response to environmental stimuli. Inhibitors of ZNF529 are developed to disrupt its ability to bind to DNA or interact with other transcriptional machinery, allowing researchers to study its specific role in gene regulation and the broader impact it may have on cellular function.
The development of ZNF529 inhibitors involves a detailed understanding of the protein's structure, particularly its zinc finger domains, which are critical for its DNA-binding capability. Structural biology techniques such as X-ray crystallography, cryo-electron microscopy, and nuclear magnetic resonance (NMR) spectroscopy are employed to determine the three-dimensional configuration of ZNF529. This structural information is essential for identifying potential binding sites where inhibitors can effectively target and block the protein's function. Computational tools like molecular docking and virtual screening are then used to identify small molecules that can specifically bind to these key regions, effectively inhibiting ZNF529's activity. Once potential inhibitors are identified, they are synthesized and subjected to rigorous in vitro testing to evaluate their binding properties, specificity, and inhibitory potency. These compounds are further refined through iterative cycles of chemical optimization to enhance their effectiveness and stability. The study of ZNF529 inhibitors not only provides valuable insights into the specific functions of this transcription factor but also contributes to a broader understanding of the molecular mechanisms that regulate gene expression and the role of zinc finger proteins in cellular biology.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
As a kinase inhibitor, Staurosporine can inhibit kinase-dependent phosphorylation that may be crucial for ZNF529's function or interaction with other proteins. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits PI3K, which could decrease AKT phosphorylation, a pathway that could be necessary for ZNF529's role in cellular signaling and function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor, which by the same mechanism as LY294002, could reduce AKT activity and potentially inhibit ZNF529 function if related to the PI3K/AKT pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 inhibits MEK, which is involved in the MAPK/ERK pathway, potentially preventing the phosphorylation and activation of ZNF529 if it is part of this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 also targets MEK in the MAPK/ERK pathway, which could inhibit the activation of ZNF529 by preventing its phosphorylation if ZNF529 is involved in this signaling cascade. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, which could lead to the inhibition of downstream pathways necessary for ZNF529's activity, particularly if ZNF529 has roles in growth and proliferation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 inhibits p38 MAP kinase, which could prevent the activation of ZNF529 if the protein is involved in stress response pathways that require p38 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125 is a JNK inhibitor, which could inhibit ZNF529 function if ZNF529 requires JNK signaling for its activation or activity in cellular processes like apoptosis or differentiation. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
Y-27632, by inhibiting ROCK, could affect cytoskeletal arrangements and cellular tension, potentially inhibiting ZNF529 if it is implicated in mechanotransduction or related signaling pathways. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib inhibits EGFR tyrosine kinase, which could inhibit downstream signaling that may be necessary for ZNF529 function in growth factor signaling pathways. |